Phase 2 N=15 Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders
Anxiety Disorders
Primary: Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients
Osteoarthritis, Knee
Primary: Safety and Tolerability of MIV-711 in Osteoarthritis (OA) Patients — 21; 2; 2; 0 Participants
Phase 2 N=136 A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology 20% Response (ACR20) (Effectiveness of LY2127399 in Treating Rheumatoid Arthritis Using the ACR20…
Phase 2 N=20 Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenia
Primary: Number of Patients for Whom Eltrombopag Increases the Platelet Count to > 50,000/uL — 6; 3; 6; 3 participants
Phase 2 N=67 Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
Multiple Myeloma
Primary: Progression Free Survival (PFS) Rate at 2 Years After Enrollment in Untreated Patients With Multiple Myeloma. — 84.6; 83.3 percentage of participants
Phase 2 N=108 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
Proliferative Diabetic Retinopathy (PDR)
Primary: Change From Baseline in Area of Neovascularizations (NVs) at End of Core Study (EOCS) — -4.6; -0.9; -1.7 square millimeters — p=0.0344
Phase 2 N=21 Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
Metastatic Esophageal Cancer · Gastroesophageal Cancer · Gastric Cancer
Primary: Response — 3; 0; 2; 0 Participants
Phase 2 N=50 Comparison of A Single Dose Combination of Methadone and Morphine With Morphine Alone for Treating Post-operative Pain
Pain
Primary: The Primary Goal of This Study is to Compare the Analgesic Effects of a Combination of Morphine and Methadone With Morphine Alone to Determine Synergistic Activity of mu…
Phase 2 N=47 Neem Lotion With Combing for Lice
Pediculoses · Head Lice
Primary: Number of Participants Free From Head Louse Infestation as Assessed by Detection Combing — 23; 22 Participants
Phase 2 N=8 Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
Aging
Primary: Change in Microbiome — 0; 0; 0 Operational Taxonomic Unit (OTU)
Phase 2 N=22 Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease
Anemia · Chronic Kidney Disease · Chronic Renal Failure
Primary: Percentage of Participants Who Experienced Increase and Maintain Hemoglobin Levels (Two Consecutive Values) Greater Than or Equal to the Lower Limit of the Target Range…
Phase 2 N=96 Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
MDS · Leukemias · Lymphomas
Primary: Engraftment as Measured by Donor Chimerism — 91 percentage of participants
Phase 2 N=35 Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Esophageal Cancer · Gastroesophageal Junction Cancer
Primary: 2-month Progression-free Survival (PFS) of Sorafenib in Patients With Metastatic or Recurrent Esophageal and Gastroesophageal (GE) Junction Cancer. — 20; 14; 1…
Phase 2 N=31 Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
Obsessive Compulsive Disorder
Primary: Yale-Brown Obsessive Compulsive Scale, Child Version (CYBOCS) — 28.20; 29.0; 26.67; 27.11 units on a scale
Phase 2 N=105 Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF
Heart Failure
Primary: Peak VO2 — 13.4; 13.8; 13.7; 13.6 ml/kg/min — p=0.2650